Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“Zelenectide Pevedotin is a Nectin-4 MMAE peptide with a different structure to classic ADCs. It’s likely to have different tox and maybe good in combos.
There isn’t a clear pathway forward but the different MOA make it important to keep in development.”
To which Niklas Klümper, Clinician Scientist and PI at Hölzel Lab, added:
“I agree!
The anti-NECTIM4 bicycle-drug conjugate Zelenectide pevedotin has demonstrated strong efficacy in mUC, especially in combination with pembro with similar ORR (also app 30% CR!) like EVP but with less neurotox and almost no skin tox!
The differentiated PK/PD of Bicycle Therapeutics peptide-based drug conjugates with high tumor penetration and fast in/ fast out (renal clearance) kinetics is super exciting!
Zele has great potential for eg triplet combination therapies (zele plus PD1 plus X) due to its favorable safety!”
Other articles about GU Oncology on OncoDaily.